Solventum Corp. (SOLV)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $15.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Solventum Corp. (SOLV) Stock Forecast
Analysts expect Solventum (SOLV) to earn $7.24 per share in the fiscal year ending Dec 31, 2026, on revenue of $8.25B. Of 15 analysts, 8 rate the stock Buy or Strong Buy, 5 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.60, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 53% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.7% |
| Buy | 7 | 46.7% |
| Hold | 5 | 33.3% |
| Sell | 1 | 6.7% |
| Strong Sell | 1 | 6.7% |
- Consensus
- Hold
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 4.1% and revenue estimates rise 3.8%.
- Fiscal year ending Dec 31, 2026
- $7.24
- EPS consensus, revenue $8.25B
- Fiscal year ending Dec 31, 2027
- $7.54
- EPS consensus, revenue $8.56B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $7.24 | $7.15 to $7.28 | 14 | $8.25B | $8.21B to $8.27B | 13 |
| Dec 31, 2027 | $7.54 | $7.18 to $7.80 | 15 | $8.56B | $8.47B to $8.63B | 13 |
Quarterly Estimates
The EPS consensus falls from $1.81 for the quarter ending Dec 31, 2026 to $1.71 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.81 | $1.72 to $1.90 | 14 | $2.13B | $2.02B to $2.21B | 14 |
| Mar 31, 2027 | $1.71 | $1.34 to $1.86 | 8 | $2.08B | $2.05B to $2.10B | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 20 upward and 5 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 8 | 3 |
| Fiscal year ending Dec 31, 2027 | 9 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.1% from $7.16.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $7.24 | $7.15 | $7.12 | $7.11 | $7.16 | +1.2% |
| Fiscal year ending Dec 31, 2027 | $7.54 | $7.27 | $7.23 | $7.23 | $7.22 | +4.5% |
| Quarter ending Mar 31, 2027 | $1.71 | $1.65 | $1.65 | $1.64 | $1.63 | +5.0% |
Frequently Asked Questions About SOLV
What is the SOLV stock forecast?
Consensus analyst estimates put Solventum's EPS at $7.24 for the fiscal year ending Dec 31, 2026, on revenue of $8.25B. The consensus rating from 15 analysts is Hold.
How do analysts rate SOLV stock?
Of 15 analysts covering Solventum, 1 rates it Strong Buy, 7 Buy, 5 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from SOLV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $7.24, with estimates from $7.15 to $7.28 from 14 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $7.54, with estimates from $7.18 to $7.80 from 15 analysts.
What revenue do analysts expect from Solventum next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $8.25B, with estimates from $8.21B to $8.27B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $8.56B, with estimates from $8.47B to $8.63B.
How many analysts cover SOLV?
15 analysts rate Solventum stock, and 14 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SOLV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors